期刊
JNCI CANCER SPECTRUM
卷 5, 期 1, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/jncics/pkaa074
关键词
-
类别
资金
- National Cancer Institute of the National Institutes of Health [U10CA180821, U10CA180882, U10CA180857, U10CA180790, U10CA180791, U10CA180795, U10CA180826, U10CA180836, U10CA180838, U10CA180867, UG1CA189858, U10CA180820, U10CA180888, U10CA180830, R01 CA169141, R01 CA118553, R01CA149222, R00CA218603, R25CA203650]
- National Institute of General Medicine Sciences of the National Institutes of Health [U54GM104940]
- Stand-Up-to-Cancer Colorectal Dream Team Grant
- Guo Shu Shi Fund
- Karen Guo Colon Cancer Research Fund
- Stone Research Fund
- Douglas Gray Woodruff Chair Fund
- Eli Lily Company
- Genentech
- Pfizer
- Sanofi
In patients with metastatic colorectal cancer, high levels of plasma IGFBP-3 and low levels of IGFBP-7 were associated with longer overall survival and progression-free survival. Extreme levels of adiponectin were linked to shorter progression-free survival, suggesting potential implications for prognostic and therapeutic innovation.
Background: Energy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study. Methods: Baseline plasma insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3, IGFBP-7, C-peptide, and adiponectin were measured at time of trial registration in a prospective cohort of patients with mCRC participating in a National Cancer Institute-sponsored trial of first-line systemic therapy. We used Cox proportional hazards regression to adjust for confounders and examine associations of each biomarker with overall survival (OS) and progression-free survival (PFS). P values are 2-sided. Results: Median follow-up for 1086 patients was 6.2 years. Compared with patients in the lowest IGFBP-3 quintile, patients in the highest IGFBP-3 quintile experienced an adjusted hazard ratio (HR) for OS of 0.57 (95% confidence interval [CI] = 0.42 to 0.78; P-nonlinearity < .001) and for PFS of 0.61 (95% CI = 0.45 to 0.82; P-trend = .003). Compared with patients in the lowest IGFBP-7 quintile, patients in the highest IGFBP-7 quintile experienced an adjusted hazard ratio for OS of 1.60 (95% CI = 1.30 to 1.97; P-trend < .001) and for PFS of 1.38 (95% CI = 1.13 to 1.69; P-trend < .001). Plasma C-peptide and IGF-1 were not associated with patient outcomes. Adiponectin was not associated with OS; there was a nonlinear U-shaped association between adiponectin and PFS (P-nonlinearity = .03). Conclusions: Among patients with mCRC, high plasma IGFBP-3 and low IGFBP-7 were associated with longer OS and PFS. Extreme levels of adiponectin were associated with shorter PFS. These findings suggest potential avenues for prognostic and therapeutic innovation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据